A phase I trial (NCT03639194) aimed at investigating safety and tolerability of ABBV-011 monotherapy or paired with budigalimab, a programmed cell death 1 inhibitor was performed in participants with relapsed or refractory SCLC though data from the dual therapy cohort has not been published [66]. The gene discussed is PDCD1; the disease is small cell lung carcinoma.